Triglav Investments D.O.O. Invests $1.32 Million in Regeneron Pharmaceuticals, Inc. $REGN

Triglav Investments D.O.O. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,515 shares of the biopharmaceutical company’s stock, valued at approximately $1,320,000.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares in the last quarter. DAVENPORT & Co LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $271,000. Rossby Financial LCC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $87,000. Keybank National Association OH grew its position in Regeneron Pharmaceuticals by 23.7% during the first quarter. Keybank National Association OH now owns 1,533 shares of the biopharmaceutical company’s stock valued at $972,000 after purchasing an additional 294 shares in the last quarter. Finally, Private Trust Co. NA increased its stake in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 19 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group lifted their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Bank of America upped their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research report on Wednesday. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $802.36.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $651.80 on Friday. The stock has a market capitalization of $69.08 billion, a P/E ratio of 15.61, a P/E/G ratio of 2.03 and a beta of 0.31. The business has a 50-day moving average of $581.80 and a two-hundred day moving average of $565.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $883.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period last year, the business earned $12.46 EPS. The firm’s revenue was up .9% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.